Posts

Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues

on
Sources: Lilly inks deals to buy 3 vaccine developers for up to $3.8B Lilly Gets Back Into the Vaccine Business With New Deals - YouTube Recon: Lilly to buy three vaccine makers for up to $3.8B - RAPS Lilly lands vaccine trifecta with 3 new biotech buys valued at up to ... Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion | Bloomberg Intelligence Eli Lilly Buys 3 Vaccine Companies in $3.8 Billion Deal to Expand Infectious Disease Push Triple Play: Lilly Acquires Three Developers of Infectious Disease ... LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio Eli Lilly to buy 3 vaccine companies for $3.8 billion Deals - Fierce Biotech Lilly Targets Vaccines With $3.8 Billion Acquisition Push Lilly and Engage Bio tie the knot with $202M acquisition - BioSpace Lilly Gets Back Into the Vaccine Business With New Deals Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology Lilly gets back in infectious disea...

Lantheus mulls potential $7B sale after Curium takeover offer – Bloomberg

on

Gilead's Hepcludex Wins FDA Approval for Hepatitis D After Prior Manufacturing Snag

on

Makary’s FDA Reforms Continue to Advance Amid Leadership Turmoil

on

All eyes on Revolution, bispecific antibodies and more at ASCO26

on

FDA Grants Daiichi Sankyo and AstraZeneca’s Datroway a Key Breast Cancer Approval

on

Lilly reports new Phase 1b data on PCSK9 base‑editing gene therapy from Verve buyout

on

Cornerstone Robotics expands global reach with EU, Singapore clearances

on

Kelun‑Biotech to Present Two Registrational NSCLC Studies in Oral Session at ASCO 2026: ADC and RET Inhibitor Data in Metastatic NSCLC Patients

on

Henlius Advances First-in-Class B7-H3 Sialidase Fusion Protein HLX316/E-688 into First-in-Human Phase 1 Trial in China

on

Biogen and Denali halt Parkinson’s drug in non‑genetic Parkinson’s after mid‑stage failure

on

AstraZeneca Wins EU Backing for Breast Cancer Drug, Splitting With FDA Panel

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on